considerations for characterizing the potential health effects from exposure to nanomaterials david...

49
Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark, Delaware, USA NNI-NIST Workshop Gaithersburg, MD September 13, 2007

Upload: alexandrina-bridges

Post on 23-Dec-2015

212 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Considerations for Characterizing the Potential Health Effects from

Exposure to Nanomaterials

David B. Warheit, PhD.

DuPont Haskell Laboratory

Newark, Delaware, USA

NNI-NIST Workshop

Gaithersburg, MD

September 13, 2007

Page 2: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Outline• Particle characterization as it relates to

• particle deposition, macrophage interactions, particle translocation

• Particle characterization for 5 studies

• Fine/Ultrafine TiO2 particle types;

• Fine/Nanoscale Quartz particle-types;

• Summary - Recommendations

Page 3: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Rat Lung Microdissection

Page 4: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Rat Lung Tissue Dissected to Demonstrate the Junction of the Terminal Airway and Proximal Alveolar Region

Page 5: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Iron Particle Deposition at Bronchoalveolar Junction

Page 6: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Iron Particle () Deposition in the Lungs of Exposed Rats

Page 7: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Iron Particle Deposition at Bronchoalveolar Junction

(Backscatter Image)

Page 8: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Alveolar Macrophage Clearance of Inhaled Iron Particles

Page 9: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Alveolar Macrophage Clearance of Inhaled Iron Particles

(Backscatter Image)

Page 10: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Alveolar Macrophage Migration to Iron Particle Deposition and Phagocytosis

Page 11: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Alveolar Macrophage Migration to Iron Particle Deposition and Phagocytosis

(Backscatter Image)

Page 12: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Macrophage phagocytosis of TiO2 particles

Page 13: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Two Alveolar Macrophages (M) Sharing a Chrysotile Asbestos Fiber () with an Alveolar Epithelial Cell (E)

MM E

Page 14: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

TEM demonstrating pathways for possible translocation of particles

Page 15: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Translocation of chrysotile asbestos fibers from airspace to epithelium

Page 16: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

1) Pulmonary Instillation Studies with Nanoscale TiO2 Rods and Dots in Rats: Toxicity is not dependent upon

Particle Size and Surface Area. Toxicol Sci., 2006

• Material characterization employed in this study:• synthesis method• crystal structure • particle size • surface area • composition/surface coating • aggregation status • cryo TEM • crystallinity • purity (TGA)

Page 17: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

2) Pulmonary bioassay studies with nanoscale and fine quartz particles in rats: Toxicity is not dependent upon particle size but on surface characteristics. Toxicol Sci.

2007

• Material characterization employed in this study:

• synthesis method • crystal structure/crystallinity (XRD)• median particle size - particle size (range) • purity (% Fe content)– ICP-AES • surface area • TEM • aggregation status• purity• surface reactivity (erythrocyte hemolysis)• reactive oxygen species (ESR) •

Page 18: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

3) Pulmonary Toxicity Study in Rats with Three Forms of ultrafine-TiO2 Particles: Differential Responses

related to Surface Properties Toxicology, 2007

• Material characterization employed in this study:• crystal phase• median particle size and size distribution in water and

PBS• pH in water and PBS• surface area (BET)• TEM • aggregation status, • chemical (surface) reactivity – (Vitamin C assay) • surface coatings/composition, purity

Page 19: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

4) Assessing toxicity of fine and nanoparticles: Comparing in vitro measurements to in vivo pulmonary toxicity

profiles. Toxicol Sci. 2007.• Particle-types utilized in this study:• Fine-sized carbonyl iron• Fine-sized crystalline silica• Fine-sized amorphous silica• Nano ZnO• Fine ZnO

• Particle characterizations conducted both in the “dry state” and “wet state”

• Material characterization employed in this study:• Particle characterization in the dry state• particle size - surface area – density - crystallinity• calculated size in dry state (based on surface area

determinations) • purity

Page 20: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

4) Assessing toxicity of fine and nanoparticles: Comparing in vitro measurements to in vivo pulmonary toxicity

profiles. Toxicol Sci. 2007. (cont)

• Particle characterization in the wet state• particle size in solutions – PBS, culture media, water

• average aggregated size in solutions,

• % distribution

• surface charge

• aggregation status

• Conversion and comparisons of in vitro and in vivo doses for dosimetric comparisons

Page 21: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

5) Comparative Pulmonary Toxicity Assessments of C60 Water Suspensions in Rats: Few Differences in Fullerene

Toxicity In Vivo in Contrast to In Vitro Profiles. Nano Lett. 2007.

• Material characterization employed in this study:• particle size and size distribution• surface charge • crystallinity • TEM • composition • oxidative radical activity (ESR measurements) • surface reactivity (erythrocyte hemolytic potential)

Page 22: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Recommendations for Minimal Essential Material Characterization for Hazard

Studies with Nanomaterials

• Particle size and size distribution (wet state) and surface area (dry state) in the relevant media being utilized – depending upon the route of exposure;

• Crystal structure/crystallinity;• Aggregation status in the relevant media;• Composition/surface coatings;• Surface reactivity;• Method of nanomaterial synthesis and/or

preparation including post-synthetic modifications (e.g., neutralization of ultrafine TiO2 particle-types);

• Purity of sample;

Page 23: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Studies to Assess Pulmonary Hazards to Nanoparticulates

Page 24: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Ultrafine TiO2 Studies

Page 25: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Pulmonary Toxicity Study in Rats with Three Forms of ultrafine-TiO2

Particles: Differential Responses related to Surface Properties

Toxicology 230: 90-104, 2007

Page 26: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Characterization of Ultrafine TiO2 Particle-types - 1

uf-3

C

300 nm

uf-2

B

300 nm

uf-1

A

300 nm

Page 27: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Characterization of Ultrafine TiO2 Particle-types - 2

SampleCrystalline

phase

Median size and width distribution

(nm) Surface area

(m2/g)

pHChemical reactivity

in water* in PBSdeionized water

in PBS

delta b*

F-1 rutile382.0± 36%

2667.2 ± 35% 5.8 7.49 6.75 0.4

uf-1 rutile136.0± 35%

2144.3± 45% 18.2 5.64 6.78 10.1

uf-2 rutile149.4± 50%

2890.7± 31% 35.7 7.14 6.78 1.2

uf-380/20

anatase/ rutile

129.4± 44%

2691.7± 31% 53.0 3.28 6.70 23.8

Page 28: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Protocol for ultrafine TiO2 Pulmonary Bioassay Study

Exposure Groups• PBS (vehicle control)• Particle-types (1 and 5 mg/kg)

o rutile-types uf-1 TiO2

o rutile-type uf-2 TiO2

o anatase/rutile-type uf-3 TiO2

o rutile-type F-1 fine TiO2 (negative control)o α-Quartz particles (positive control)

Instillation Exposure

24 hr 1 wk 1 mo 3 mo

Postexposure Evaluation via BAL and Lung Tissue

Page 29: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

RESULTSBiomarkers

Pulmonary InflammationPulmonary CytotoxicityLung cell Proliferation

Page 30: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Pulmonary Inflammation

Page 31: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

BAL Fluid LDH Values (cytotoxicity)

Page 32: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Pulmonary Cell Proliferation Rates

Page 33: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Lung Sections of Rats exposed to uf-1 (A); uf-2 (B); or F-1 (C)- 3 months pe

Page 34: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Lung Section of Rat exposed to uf-3 3 months postexposure

Page 35: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Lung Section of Rat exposed to Quartz particles - 3 months postexposure

Page 36: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Nanoscale Quartz

Page 37: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Pulmonary Bioassay Studies with Nanoscale and Fine Quartz Particles

in Rats: Toxicity is not Dependent upon Particle Size but on Surface

Characteristics

Toxicol Sci. 95:270-280, 2007

Page 38: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Nanoscale Quartz Particles

Page 39: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Characterization of Nanoscale Quartz Particles

Sample

Average size (nm)

Size range

(nm)

Surface area (m2/g) Crystallinity

ICP-AES (% Fe content)

Nanoquartz I 50 30-65 31.4 α-Quartz 0.080%

Nanoquartz II 12 10-20 90.5α-Quartz

0.034%

Fine quartz 300 100-500 4.2α-Quartz

0.011%

Min-U-Sil 534 300-700 5.1α-Quartz

0.042%

Page 40: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Pulmonary Inflammation – Nanoscale Quartz study

Percent Neutrophils in BAL Fluids of Rats exposed to Fine and Nano-sized Quartz Particles (Study #2)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

5 mg/kg 1 mg/kg 5 mg/kg 1 mg/kg 5 mg/kg 1 mg/kg 5 mg/kg

PBS CarbonylIron

particles

Min-U-Sil quartz particles Nano quartz II particles Fine quartz particles

Exposure Groups

% P

MN

s

24 Hour 1 Week 1 Month 3 Month

**

*

***

*

*

***

*

*

Page 41: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

BAL Fluid LDH Values – Nanoscale Quartz study

BAL Fluid LDH Values in Rats exposed toFine and Nano-sized Quartz Particles (Study #2)

0

100

200

300

400

500

600

700

800

0.5 mls 5 mg/Kg 1 mg/Kg 5 mg/Kg 1 mg/Kg 5 mg/Kg 1 mg/Kg 5 mg/Kg

PBS CarbonylIron

particles

Min-U-Sil quartz particles Nano quartz II particles Fine quartz particles

Exposure Groups

BA

L f

luid

LD

H v

alu

es

(u/L

)

24 Hour 1 Week 1 Month 3 Month

*

*

*

*

**

*

*

Page 42: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Lung Parenchymal Cell Proliferation– Nanoscale Quartz study

Lung Parenchymal Cell Proliferation rates of rats exposed to Nano-Quartz and other particulates

0.00%

0.20%

0.40%

0.60%

0.80%

1.00%

1.20%

5 mg/kg 1 mg/kg 5 mg/kg 1 mg/kg 5 mg/kg 1 mg/kg 5 mg/kg

PBS CarbonylIron

Min-U-Sil quartz particles Nano quartz II particles Fine quartz particles

Exposure Groups

Pe

rce

nt

Pro

life

rati

ng

Ce

lls

24 Hour 1 Week 1 Month 3 Month

*

*

**

Page 43: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Lung Tissue Sections – Control (A); Min-U-Sil (B); NanoQ II (C); Fine Quartz (D).

A B

C D

Page 44: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

The hemolytic potential of the four -quartz samples used in the study. The samples, including:

These samples show a similar trend as the inflammation, cytotoxicity, and cell proliferation data.

Hemolytic Potential of -Quartz Samples

nano-quartz II = Min-U-Sil > fine-quartz > nano-quartz I

Hemolytic potential is a measure of surface reactivity.

• Min-U-Sil• fine-quartz• nano-quartz I• nano-quartz II

Nano-quartz II (NQ-2) 12 nm

0

0.2

0.4

0.6

0.8

1

1.2

1.4

Blank PBS TritonX100

15.000 7.500 3.750 1.875 0.938 0.469 0.234 0.117 0.059

Concentration (mg/mL)

AB

S @

540

nm

Nano-quartz I (NQ-1) 50 nm

0

0.2

0.4

0.6

0.8

1

1.2

1.4

Blank PBS TritonX100

15.000 7.500 3.750 1.875 0.938 0.469 0.234 0.117 0.059

AB

S @

540 n

m

Fine-quartz (FQ-1) Silica 300 nm

0

0.2

0.4

0.6

0.8

1

1.2

1.4

Blank PBS TritonX100

15.000 7.500 3.750 1.875 0.938 0.469 0.234 0.117 0.059

AB

S @

54

0 n

m

Crystalline Silica (Min-U-Sil) 534 nm

0

0.2

0.4

0.6

0.8

1

1.2

1.4

Blank PBS TritonX100

15.000 7.500 3.750 1.875 0.938 0.469 0.234 0.117 0.059

AB

S @

54

0 n

m

Crystalline Silica (Min-U-Sil 5) 534 nm

Fine Quartz 300 nm

Nano Quartz I 50 nm

Nano Quartz II 12 nm

Concentration (mg/mL)

AB

S @

540

nm

Page 45: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Summary of α-Quartz Results

Endpoint Min-U-Sil Nanoquartz I Nanoquartz II Fine quartzParticle size ++++ ++ + +++

Surface area + +++ ++++ ++

Fe content ++ +++ ++ +

Crystallinity ++++ ++++ ++++ ++++

Radical content ++++ ++ +++ -

Hemolytic content +++ + +++ ++

Lung inflammation +++ ++ +++ ++

Cytotoxicity +++ ++ +++ +

Airway BrdU ++ N/A ++ +

Lung parenchymal BrdU

++ N/A ++ +

Histopathology +++ N/A ++++ ++

Page 46: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Fullerene Water Suspensions Characterization

Nano-C60 C60(OH)24

FWSSize and Size Distribution

Surface Charge Crystallinity

nano-C60 160 ± 50 nm - 36 mV simple hexagonal

C60(OH)24 <2 nm 0 not crystalline

OHOH

OH

OH

HO

HO

OH

OHHO

HO

HOOH

OHHO

OHOH

Page 47: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

200 nm

Nano-C60 characterization

50 100 150 200 2500

50

100

150

200

Pop

ulat

ion

Size (nm)

Fullerene Water Suspensions Characterization

Page 48: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Recommendations for Minimal Essential Material Characterization for Hazard

Studies with Nanomaterials

• Particle size and size distribution (wet state) and surface area (dry state) in the relevant media being utilized – depending upon the route of exposure;

• Crystal structure/crystallinity;• Aggregation status in the relevant media;• Composition/surface coatings;• Surface reactivity;• Method of nanomaterial synthesis and/or

preparation including post-synthetic modifications (e.g., neutralization of ultrafine TiO2 particle-types);

• Purity of sample;

Page 49: Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,

Acknowledgments• This study was supported by DuPont

Central Research and Development. • Tom Webb and Ken Reed provided the

pulmonary toxicology technical expertise for the study. Dr. Christie Sayes – postdoctoral fellow. Denise Hoban, Elizabeth Wilkinson and Rachel Cushwa conducted the BAL fluid biomarker assessments. Carolyn Lloyd, Lisa Lewis, John Barr prepared lung tissue sections and conducted the BrdU cell proliferation staining methods. Don Hildabrandt provided animal resource care.